Consideration of Pannexin 1 channels in COVID-19 pathology and treatment.
作者信息
Swayne Leigh Anne, Johnstone Scott R, Ng Chen Seng, Sanchez-Arias Juan C, Good Miranda E, Penuela Silvia, Lohman Alexander W, Wolpe Abigail G, Laubach Victor E, Koval Michael, Isakson Brant E
机构信息
Division of Medical Sciences, University of Victoria, Victoria, British Columbia, Canada.
Fralin Biomedical Research Institute at Virginia Tech Carilion Center for Heart and Reparative Medicine Research, Virginia Tech, Roanoke, Virginia.
出版信息
Am J Physiol Lung Cell Mol Physiol. 2020 Jul 1;319(1):L121-L125. doi: 10.1152/ajplung.00146.2020. Epub 2020 Jun 10.
Abstract
摘要
相似文献
1
Consideration of Pannexin 1 channels in COVID-19 pathology and treatment.
Am J Physiol Lung Cell Mol Physiol. 2020 Jul 1;319(1):L121-L125. doi: 10.1152/ajplung.00146.2020. Epub 2020 Jun 10.
2
Ritonavir- and lopinavir-induced eryptosis in a SARS-CoV-2-infected patient.
Blood. 2020 Aug 13;136(7):915. doi: 10.1182/blood.2020006228.
3
Atypical lymphocyte morphology in SARS-CoV-2 infection.
Pathol Res Pract. 2020 Sep;216(9):153063. doi: 10.1016/j.prp.2020.153063. Epub 2020 Jun 10.
4
Sofosbuvir for COVID-19 infection: A potential candidate.
Indian J Pharmacol. 2020 May-Jun;52(3):232-233. doi: 10.4103/ijp.IJP_675_20. Epub 2020 Aug 4.
5
Evidence of SARS-CoV-2 mRNA in endomyocardial biopsies of patients with clinically suspected myocarditis tested negative for COVID-19 in nasopharyngeal swab.
Cardiovasc Res. 2020 Aug 1;116(10):1661-1663. doi: 10.1093/cvr/cvaa160.
6
[Not Available].
Rev Med Suisse. 2020 Apr 29;16(N° 691-2):878.
7
Virology, transmission, and pathogenesis of SARS-CoV-2.
BMJ. 2020 Oct 23;371:m3862. doi: 10.1136/bmj.m3862.
8
Coronavirus disease 2019 infection and the cardiovascular system.
J Cardiovasc Med (Hagerstown). 2020 Jun;21(6):403-405. doi: 10.2459/JCM.0000000000000980.
9
Dexamethasone nanomedicines for COVID-19.
Nat Nanotechnol. 2020 Aug;15(8):622-624. doi: 10.1038/s41565-020-0752-z.
10
Imatinib for COVID-19: A case report.
Clin Immunol. 2020 Sep;218:108518. doi: 10.1016/j.clim.2020.108518. Epub 2020 Jun 27.
引用本文的文献
1
Pharmacological mechanisms of probenecid for SARS-CoV-2 and RSV co-infection: findings of system pharmacology, molecular docking, molecular dynamics simulation, and structure-activity relationship.
Front Microbiol. 2025 Apr 30;16:1552603. doi: 10.3389/fmicb.2025.1552603. eCollection 2025.
2
Probenecid Inhibits Influenza A(H5N1) and A(H7N9) Viruses In Vitro and in Mice.
Viruses. 2024 Jan 19;16(1):152. doi: 10.3390/v16010152.
3
Overlap in synaptic neurological condition susceptibility pathways and the neural pannexin 1 interactome revealed by bioinformatics analyses.
Channels (Austin). 2023 Dec;17(1):2253102. doi: 10.1080/19336950.2023.2253102. Epub 2023 Oct 8.
4
SARS-CoV-2 E and 3a Proteins Are Inducers of Pannexin Currents.
Cells. 2023 May 25;12(11):1474. doi: 10.3390/cells12111474.
5
The Potential of Purinergic Signaling to Thwart Viruses Including SARS-CoV-2.
Front Immunol. 2022 Jun 17;13:904419. doi: 10.3389/fimmu.2022.904419. eCollection 2022.
6
Mechanisms of SARS-CoV-2 and Male Infertility: Could Connexin and Pannexin Play a Role?
Front Physiol. 2022 May 23;13:866675. doi: 10.3389/fphys.2022.866675. eCollection 2022.
7
Effects of Drugs Formerly Suggested for COVID-19 Repurposing on Pannexin1 Channels.
Int J Mol Sci. 2022 May 18;23(10):5664. doi: 10.3390/ijms23105664.
8
The effect of the delta SARS-CoV-2 variant on maternal infection and pregnancy.
iScience. 2022 May 20;25(5):104295. doi: 10.1016/j.isci.2022.104295. Epub 2022 Apr 25.
9
Repurposing Probenecid to Inhibit SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus (RSV) Replication.
Viruses. 2022 Mar 15;14(3):612. doi: 10.3390/v14030612.
10
Possible role of pannexin 1 channels and purinergic receptors in the pathogenesis and mechanism of action of SARS-CoV-2 and therapeutic potential of targeting them in COVID-19.
Life Sci. 2022 May 15;297:120482. doi: 10.1016/j.lfs.2022.120482. Epub 2022 Mar 11.
本文引用的文献
1
Remdesivir for the Treatment of Covid-19 - Final Report.
N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8.
2
Urgent reconsideration of lung edema as a preventable outcome in COVID-19: inhibition of TRPV4 represents a promising and feasible approach.
Am J Physiol Lung Cell Mol Physiol. 2020 Jun 1;318(6):L1239-L1243. doi: 10.1152/ajplung.00161.2020. Epub 2020 May 13.
3
Respiratory disease in rhesus macaques inoculated with SARS-CoV-2.
Nature. 2020 Sep;585(7824):268-272. doi: 10.1038/s41586-020-2324-7. Epub 2020 May 12.
4
Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures.
Lancet Respir Med. 2020 Jul;8(7):687-695. doi: 10.1016/S2213-2600(20)30193-4. Epub 2020 May 7.
5
The many faces of the anti-COVID immune response.
J Exp Med. 2020 Jun 1;217(6). doi: 10.1084/jem.20200678.
6
SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes.
Nat Med. 2020 May;26(5):681-687. doi: 10.1038/s41591-020-0868-6. Epub 2020 Apr 23.
7
Endothelial Pannexin 1 Channels Control Inflammation by Regulating Intracellular Calcium.
J Immunol. 2020 Jun 1;204(11):2995-3007. doi: 10.4049/jimmunol.1901089. Epub 2020 Apr 20.
8
Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?
Am J Physiol Endocrinol Metab. 2020 May 1;318(5):E587-E588. doi: 10.1152/ajpendo.00136.2020.
9
Coronavirus membrane fusion mechanism offers a potential target for antiviral development.
Antiviral Res. 2020 Jun;178:104792. doi: 10.1016/j.antiviral.2020.104792. Epub 2020 Apr 6.
10
Metabolites released from apoptotic cells act as tissue messengers.
Nature. 2020 Apr;580(7801):130-135. doi: 10.1038/s41586-020-2121-3. Epub 2020 Mar 18.
Zotero 插件